atNorth Announces 30MW metro data center in Stockholm, Sweden

The new heat reuse enabled data center, located near to the company's SWE01 site, will allow customers to deploy seamlessly connected clusters across both locations. atNorth, the leading Nordic high-density colocation and built-to-suit datacenter provider, has announced its plans to build an additional data center in Stockholm bringing its total number of Nordic data centers […]

Klarna Group plc Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – KLAR

The DJS Law Group reminds investors of a class action lawsuit against Klarna Group plc (“Klarna” or “the Company”) (NYSE: KLAR) for violations of the federal securities laws. Shareholders who purchased shares of KLAR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is

Contiem teamed with IBM to support the UK Ministry of Defence in generating an AI-powered DEEAMS Logistics Upgrade

Contiem, a global provider of content-related software and services, today announced that IBM has selected it as part of the delivery team for the UK Ministry of Defence’s (MoD) Defence Equipment Engineering Asset Management System (DEEAMS) programme. The DEEAMS initiative is a revolutionary, AI-driven, modernisation programme designed to replace 17 fragmented, siloed, and outdated applications

CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to

CoreWeave, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – CRWV

The DJS Law Group reminds investors of a class action lawsuit against CoreWeave, Inc. (“CoreWeave ” or “the Company”) (NASDAQ: CRWV ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CRWV during the

CRWV Investors Have Opportunity to Lead CoreWeave, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CoreWeave, Inc. (“CoreWeave” or “the Company”) (NASDAQ: CRWV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the

Corcept Therapeutics Incorporated Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights – CORT

The DJS Law Group announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. On December 31, 2026, Corcept

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (NASDAQ: VTGN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased

Vistagen Therapeutics, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – VTGN

The DJS Law Group reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen ” or “the Company”) (NASDAQ: VTGN ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of VTGN during

Scroll to Top